SITC

Articles

A study presented at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting suggested that ipilimumab (Yervoy) plus nivolumab (Opdivo) for patients with metastatic or unresectable angiosarcoma was well-tolerated.

Ipilimumab Plus Nivolumab Promising for Patients with Metastatic or Unresectable Angiosarcoma

“The data reported, in addition to its ease of use, demonstrate the potential of [tavokinogene telseplasmid] in combination with pembrolizumab as a next-generation intratumoral IL-12 therapy that can induce regression of both locally treated and untreated distant and visceral lesions,” said Paolo A. Ascierto, MD.

Tavokinogene Telseplasmid, Pembrolizumab Combo Promising in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

Videos

Marjorie Zauderer, MD, from Memorial Sloan Kettering Cancer Center, discussed new immunotherapy approaches at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Marjorie Zauderer, MD, on New Immunotherapy Approaches

Domenico Mallardo, MD, Istituto Nazionale Tumori "Fondazione Pascale" in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Domenico Mallardo, MD, on Anti-CTLA4 Agents in Melanoma

Luca Biavati, MD, from Johns Hopkins Medicine, discussed bone marrow T-cells and bone marrow infiltrating lymphocytes as a source for adoptive cell therapy at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Luca Biavati, MD, on Bone Marrow T-Cells for Adoptive Cell Therapy

Robert Ferris, MD, from UPMC Hillman Cancer Center, discusses the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019), and how immunotherapy will continue to transform cancer treatment.

Robert Ferris, MD, on Immunotherapy Transforming Cancer Treatment

Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Jason Williams, MD, on Intratumoral Immunotherapy Advances at SITC 2019

Joshua Brody, MD, discusses the gratification of the crossover between medicine and science at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Joshua Brody, MD, on Cross-Section of Science and Medicine at SITC 2019

Mario Sznol, MD, from Yale University, discusses where the field of immune-oncology will be 1 and 5 years from now at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Mario Sznol, MD on the Future of Addressing Drug Resistance

 The increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events  that have proven to be extremely challenging to manage.

SITC | Conference